In this article, the role of cultural capital in strengthening social trust in Iran has been studied. Social trust is one of the most important components of social development. It is one of the important aspects of social relations. Cultural capital, which is an indicator of cultural development, is used objectively and the scientific and cultural qualities of a person can affect social trust....

Edge of Things (EoT) technology enables end-users participation with smart sensors and mobile devices (such as smartphones wearable devices) to the across city. Trust management is main challenge in EoT infrastructure consider trusted participants. The Quality Service (QoS) highly affected by malicious users fake or altered data. In this article, a robust trust (RTM) scheme designed based on Ba...

In this concluding essay I shall try to reconstruct what seem to me the central questions about trust that the individual contributions presented in this volume raise and partly answer. In the first section, I briefly qualify the claim that there is a degree of rational cooperation that should but does not exist, and I shall give a preliminary indication of the importance of the beliefs we hold...

We build a simple model of trust as an equilibrium phenomenon, departing from standard “selfish” preferences in a minimal way. Agents who are on the receiving end of an offer to transact can choose whether to cheat and take away the entire surplus, taking into account a “cost of cheating.” The latter has an idiosyncratic component (an agent’s type), and a socially determined one. The smaller th...

In Social networks, users need a proper estimation of trust in others to be able to initialize reliable relationships. Some trust evaluation mechanisms have been offered, which use direct ratings to calculate or propagate trust values. However, in some web-based social networks where users only have binary relationships, there is no direct rating available. Therefore, a new method is required t...

TaRceva LUng cancer Survival Treatment (TRUST) was an open-label, phase IV study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for chemotherapy or radiotherapy received erlotinib 150 mg/day until progression. We examined a subpopulation of elderly patients (≥70 years) receiving first-line erlotinib (n=485) in TRUST. In this subpopulation, disease control rate (n...